SCM LifeScience Co

SCM LifeScience Co R&D Expenses

The Research & Development Expenses of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is 1.94 B KRW. In the previous year, Research & Development Expenses was 7.60 B KRW — a change of -74.50% (lower).

R&D Expenses

1.94 BKRW

YoY

-74.50%

Last updated:

Research & Development Expenses of SCM LifeScience Co is 2025 1.94 B KRW. Research & Development Expenses of SCM LifeScience Co was 2024 7.60 B KRW. It decreases by -74.50% lower compared to the previous year.

The SCM LifeScience Co R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
6.97 B KRW
Jan 1, 2020
8.85 B KRW
Jan 1, 2021
10.47 B KRW
Jan 1, 2022
9.31 B KRW
Jan 1, 2023
9.31 B KRW
Jan 1, 2024
7.60 B KRW
Jan 1, 2025
1.94 B KRW
The SCM LifeScience Co R&D Expenses history
YEARR&D ExpensesYoY
1.94 BKRW-74.50%
7.60 BKRW-18.46%
9.31 BKRW+0.04%
9.31 BKRW-11.09%
10.47 BKRW+18.40%
8.85 BKRW+26.95%
6.97 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Research & Development Expenses of SCM LifeScience Co is 1.94 B KRW in 2025.

Research & Development Expenses of SCM LifeScience Co changed from 7.60 B KRW to 1.94 B KRW, representing a -74.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's SCM LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co